JP2012046489A5 - - Google Patents

Download PDF

Info

Publication number
JP2012046489A5
JP2012046489A5 JP2011151340A JP2011151340A JP2012046489A5 JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5 JP 2011151340 A JP2011151340 A JP 2011151340A JP 2011151340 A JP2011151340 A JP 2011151340A JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5
Authority
JP
Japan
Prior art keywords
cancer
cells
virus
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011151340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012046489A (ja
Filing date
Publication date
Priority claimed from AU2002953436A external-priority patent/AU2002953436A0/en
Application filed filed Critical
Publication of JP2012046489A publication Critical patent/JP2012046489A/ja
Publication of JP2012046489A5 publication Critical patent/JP2012046489A5/ja
Pending legal-status Critical Current

Links

JP2011151340A 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 Pending JP2012046489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2002953436 2002-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004559490A Division JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Publications (2)

Publication Number Publication Date
JP2012046489A JP2012046489A (ja) 2012-03-08
JP2012046489A5 true JP2012046489A5 (enExample) 2012-10-11

Family

ID=30004521

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
JP2011151340A Pending JP2012046489A (ja) 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Country Status (11)

Country Link
US (2) US7485292B2 (enExample)
EP (1) EP1581257B1 (enExample)
JP (2) JP2006517189A (enExample)
KR (1) KR101171295B1 (enExample)
CN (2) CN102166228B (enExample)
AU (1) AU2002953436A0 (enExample)
CA (1) CA2510227C (enExample)
ES (1) ES2463678T3 (enExample)
NZ (1) NZ541230A (enExample)
WO (1) WO2004054613A1 (enExample)
ZA (1) ZA200505389B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP1793851B1 (en) 2004-08-20 2016-10-05 Viralytics Limited Methods and compositions for treatment of hematologic cancers
EP1843773A4 (en) * 2005-01-17 2008-07-30 Viralytics Ltd METHOD AND COMPOSITION FOR TREATING NEOPLASIA
US9566307B2 (en) 2012-04-19 2017-02-14 Kyushu University, National University Corporation Pharmaceutical composition
PL2826856T3 (pl) 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
EP4019029A1 (en) 2016-09-27 2022-06-29 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
CN110461323A (zh) 2017-03-31 2019-11-15 绪方久修 溶瘤病毒的增殖方法和抗肿瘤剂
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
JPH04504361A (ja) 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
AU2252092A (en) * 1991-06-24 1993-01-25 Research Foundation Of The State University Of New York, The De novo cell-free synthesis of picornavirus
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0931830B1 (en) 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and phophylaxis of neoplasia
EP1314431B1 (en) 1993-04-30 2008-07-16 Wellstat Biologics Corporation Purified compositions of Newcastle disease virus
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP2001519175A (ja) 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania REPLICATING VIRUS PRODUCING CELLS FOR TREATING MALIGNANCY
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP1695714B1 (en) 1999-02-05 2008-07-30 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
ES2320239T3 (es) 1999-09-17 2009-05-20 Wellstat Biologics Corporation Virus oncolitico.
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
DE60035124T2 (de) 1999-11-15 2008-02-07 Onyx Pharmaceuticals, Inc., Emeryville Ein oncolytisches adenovirus
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
PT1252322E (pt) 2000-01-21 2005-03-31 Biovex Ltd Estirpes de virus de herpes para terapia genica
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU2001268146B2 (en) 2000-06-01 2005-09-22 Sloan-Kettering Institute For Cancer Research Use of mutant herpes viruses and anticancer agents in the treatment of cancer
AU2002220416A1 (en) 2000-12-01 2002-06-11 University Of Ottawa Oncolytic virus
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
EP1406668A1 (en) 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
ES2539941T3 (es) 2001-05-09 2015-07-07 Takara Bio, Inc. Composición y método para tratar el cáncer usando herpes virus
MXPA03010278A (es) 2001-05-11 2004-12-06 Wellstat Biologics Corp Terapia con virus oncolitico.
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
EP1409653A4 (en) 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
JP2005519091A (ja) 2002-03-01 2005-06-30 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の再発及び転移の予防
CA2479763A1 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
EP1499332A4 (en) 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
ES2239928T3 (es) 2002-05-09 2009-02-16 Oncolytics Biotech Inc. Metodo para reducir el dolor utilizando virus oncoliticos.
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
EP1648233A4 (en) 2003-07-08 2006-08-23 Univ Arizona MUTANTS OF VACCINIA VIRUS AS ONCOLYTICA
MXPA06003318A (es) 2003-09-26 2006-06-08 Novartis Ag Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad.
CN101027394A (zh) 2004-03-11 2007-08-29 维若塔歌私人有限公司 修饰的溶瘤病毒
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8080240B2 (en) 2004-10-21 2011-12-20 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Similar Documents

Publication Publication Date Title
JP2012046489A5 (enExample)
Roy et al. Lycorine: A prospective natural lead for anticancer drug discovery
Marcucci et al. How to improve exposure of tumor cells to drugs—Promoter drugs increase tumor uptake and penetration of effector drugs
Ramaekers et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons
NZ717490A (en) Methods of treating cancer
Bouche Compression and entrapment neuropathies
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
Cheng et al. Metal‐Doping Strategy for Carbon‐Based Sonosensitizer in Sonodynamic Therapy of Glioblastoma
JP2014530873A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
JP2013189456A5 (enExample)
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
Tai et al. Fermented wheat germ extract induced cell death and enhanced cytotoxicity of cisplatin and 5‐fluorouracil on human hepatocellular carcinoma cells
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
JP2014523398A5 (enExample)
JP2018522028A5 (enExample)
JP2015506352A5 (enExample)
JP2015044878A5 (enExample)
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
CN103239464A (zh) 淫羊藿次苷ii在制备肿瘤化疗药物增敏剂中的用途
Isakoff et al. Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
Mierzejewska et al. Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner—the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling
Marzuillo et al. Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia
Elhaj et al. Male breast cancer patients: a retrospective study of patients characteristics and treatment outcome at the National Cancer Institute (NCI-UG)-Central Sudan